The allotment status for the ₹1,757.00 crore Symbiotec Pharmalab IPO is expected to be announced today, August 28, 2026. Investors can check their IPO allotment status on the official websites of the NSE, BSE, and the IPO registrar, MUFG Intime India Private Limited.

Following the completion of the allotment process, the shares are tentatively scheduled to be listed on the NSE and BSE on September 1, 2026.

Procedure to Check Symbiotec Pharmalab IPO Allotment Status Online on NSE

Visit the NSE’s IPO allotment verification status page here.
Select “Equity & SME IPO Bid Details”.
In Select, choose “SYMBIOTEC”.
Enter your PAN No. and Application No.
Click “Submit”.

Procedure to Check Symbiotec Pharmalab IPO Allotment Status Online on BSE

Click here to visit the application status page.
Under Issue Type, select “Equity”.
In Issue Name, select “Symbiotec Pharmalab Limited”.
Enter your “Application No. or PAN No.”
Enter the given Captcha correctly.
Click “Submit”.

Procedure to Check Symbiotec Pharmalab IPO Allotment Status on MUFG Intime India (Registrar to the issue)

Visit MUFG Intime India’s IPO allotment status page here.
In the “Select company”, choose “Symbiotec Pharmalab Limited”.
Enter any of the following details:

PAN
App. No.
DP/Client ID
Account No/ IFSC

Click “Submit”.

Symbiotec Pharmalab IPO - Issue Details

Issue Type: Book Built Issue (Fresh Issue + OFS)
Total Issue Size: Up to ₹1,757.00 crore
Fresh Issue: Up to ₹150.00 crore
Offer for Sale (OFS): Up to ₹1,607.00 crore
Face Value: ₹2 per equity share
Price Band: ₹938 to ₹988 per share
Lot Size: 15 shares
Minimum Investment Amount (Retail Investor): ₹14,820 (15 shares at the upper price)
Listing: BSE, NSE
Book Running Lead Managers: JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory and Securities (India) Private Limited
Registrar: MUFG Intime India Private Limited

Explore other Upcoming IPOs on BSE and NSE.

Symbiotec Pharmalab Mart IPO Overall Subscription Status

[August 27, 2026, 7:00 P.M.]

Category	Subscription (x)
Qualified Institutional Buyers (QIBs)	172.03X
Non-Institutional Investors (NIIs)	73.63x
Retail Individual Investors (RIIs)	12.96x
Total	71.26x

Utilisation of IPO Proceeds

The company intends to utilise the net proceeds from the fresh issue towards:

Prepayment and/or repayment, in full or in part, of all or a portion of certain outstanding borrowings availed by the company
General corporate purposes.

About Symbiotec Pharmalab Limited

Incorporated in 2002, Symbiotec Pharmalab Limited is a research-driven pharmaceutical and biotechnology company engaged in the development and manufacture of active pharmaceutical ingredients (APIs), complex injectables, and biotechnology-based products. It is a leading global manufacturer of corticosteroid and steroidal hormone APIs by production volume, with a portfolio of over 60 APIs.

The company operates vertically integrated manufacturing facilities in Madhya Pradesh for API production, fermentation, and injectable manufacturing. In addition to its own products, Symbiotec provides contract development and manufacturing (CDMO) services to pharmaceutical and nutraceutical companies across regulated global markets.

Key Financial Highlights

Particulars	FY26 (in ₹ crore)	FY25 (in ₹ crore)	FY24 (in ₹ crore)
Revenue from operations	869.15	751.55	716.25
EBITDA	231.97	206.11	177.04
Profit After Tax (PAT)	109.90	96.79	100.05